Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.69 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.40 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782631 | 0.89 | ENPP3 (0.61) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407437 | 0.85 | ENPP3 (0.54) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407323 | 0.85 | ENPP3 (0.52) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407628 | 0.85 | ENPP3 (0.52) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407332 | 0.85 | ENPP3 (0.50) | ENPP3ENPP1EGFRGAKRIPK2 | |
| SCHEMBL22407545 | 0.84 | TLR8 (0.60) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407599 | 0.84 | ENPP3 (0.51) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| SCHEMBL22407379 | 0.84 | ENPP3 (0.53) | ENPP3ENPP1TLR8HTR1AADRA1D | |
| Methane SCHEMBL28438541 | 0.84 | ENPP3 (0.49) | ENPP3ENPP1EGFRGAKRIPK2 | |
| SCHEMBL20770860 | 0.84 | ENPP3 (0.53) | ENPP3ENPP1TLR8HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514331-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | PETRAGEN, INC. (US) | 2025-03-05 | — | — | EP | claimed |
| WO-2023212154-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | Petragen, Inc. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230346771-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | Petragen, Inc. | 2023-11-02 | — | — | US | claimed |
| EP-4514331-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | PETRAGEN, INC. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023212154-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | Petragen, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20230346771-A1 | INHIBITORS OF ENPP1 AND MODULATION OF BONE GROWTH | Petragen, Inc. | 2023-11-02 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3676254-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | AbbVie Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111315723-A | Extramembranous nucleotide pyrophosphatase-phosphodiesterase 1(ENPP-1) inhibitor and application thereof | 艾伯维公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP3 2/4885ENPP1 1/4885TLR8 1420/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP3 2/4885ENPP1 1/4885TLR8 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.